This is a global site of Sanofi and is intended only for healthcare professionals.
Please select your country of practice:
By proceeding to the global site you are confirming you are a healthcare professional residing in the country selected above.
This site is not available in your country.
If you are not a healthcare professional please refer to your doctor, as this global site is intended for healthcare professionals only.
Dedicated to the Multiple Myeloma Community
At Sanofi, we are committed to helping patients with multiple myeloma, including relapsed
and refractory multiple myeloma.
There are unmet medical needs for high-risk subgroups
Multiple myeloma does not impact all patients the same way. Some groups of patients, in particular elderly patients, patients with cytogenetic abnormalities, patients with renal impairment, and relapsed/refractory patients, face additional risks and complications.1-4
Positive outcomes can start with MRD negativity
Achieving minimal residual disease negativity (MRD-) has been shown to improve progression-free survival and overall survival. Discover a multiple myeloma treatment option that has demonstrated high rates of MRD- in trials.5-7
Can research keep up with multiple myeloma?
Each year, there are more than 130,000 new diagnoses of multiple myeloma worldwide. Of those 130,000 new diagnoses, 39,000 of those patients are in Europe. For the EU as a whole, multiple myeloma incidence is projected to increase from approximately 35,000 new cases in 2015 to over 43,000 by 2030.8-10
Approximately 39,000 EU patients diagnosed annually10
Many will relapse and risk becoming refractory to treatment4,11
New research is required to keep up with disease progression4,11
1. Willan J, Eyre TA, Sharpley F, et al. Multiple myeloma in the very elderly (…). Clin Interv Aging. 2016;11:423-435. 2. Schmidt TM, Barwick BG, Joseph N, et al. Gain of Chromosome 1q is associated with (…). Blood Cancer J. 2019;9(12):94. 3. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma (…). Leuk Lymphoma. 2007;48(2):337-341. 4. Larsen JT, Kumar S. Evolving paradigms in the management of multiple myeloma (…). Rare Cancers Ther. 2015;3(1):47-68. 5. Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Minimal residual disease in multiple myeloma (…). Front Oncol. 2020;10:860. 6. Landgren O, Iskander K. Modern multiple myeloma therapy (…). J Intern Med. 2017;281(4):365-382. 7. Moreau P, Dimopoulos M-A, Mikhael J, et al. Multinational Clinical Study Comparing (…). Lancet. 2021;397(10292):2361-2381. 8. International Myeloma Foundation. March Myeloma Action Month website. Accessed March 2021. https://mam.myeloma.org/learn-more-about-multiple-myeloma/ 9. Schey SA, Morris J, Maguire Á, Dhanasiri S. Quantifying the burden of multiple myeloma (…). Blood. 2016;128(22):5960. 10. João C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, Silva MG. Long-term survival in multiple myeloma. Clin Case Rep. 2014;2(5):173-179. doi:10.1002/ccr3.76 11. Abramson HN. The multiple myeloma drug pipeline-2018 (…). Clin Lymphoma Myeloma Leuk. 2018;18(9):611-627.